EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SOHO State of the Art Updates and Next Questions | Individualizing Treatment Selection in Myelofibrosis

Anthony M Hunter, Prithviraj Bose

Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · 640-648

DOI: 10.1016/j.clml.2026.07.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Anthony M Hunter und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Precision Medicine, Janus Kinase Inhibitors. Die Arbeit nennt 120 Literaturangaben. Gefördert von: NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelofibrosis is an advanced myeloproliferative neoplasm that is biologically driven by constitutively active JAK-STAT signaling. Resultant effects on hematopoiesis and inflammatory cytokine signaling give rise to an array of clinical manifestations that include proliferative features, splenomegaly, constitutional symptoms, cytopenias, propensity towards leukemic transformation, and risk of thrombosis, with patients exhibiting a high degree of variability in regard to clinical course. This necessitates an individualized treatment approach that accounts for a variety of clinical and therapy-specific factors. JAK inhibitors have emerged as the cornerstone of therapy. With 4 agents now approved in the class, selecting the appropriate agent is of critical importance. In this review we discuss key variables that should be considered in the creation of a therapeutic plan for patients with myelofibrosis. We will review pharmacologic differences between available JAK inhibitors, discuss the patient factors that drive therapy decisions in myelofibrosis, and highlight emerging therapies in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPrecision MedicineJanus Kinase InhibitorsHumansProtein Kinase InhibitorsSignal Transduction

Stichwörter der Autor:innen

JAK inhibitorsJAK2MPNsMyelofibrosisMyeloproliferative neoplasms

Substanzen

Janus Kinase InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: pbose@mdanderson.org.

Förderung

  • NIH

Zitieren

APA

Hunter, A. M., & Bose, P. (2026). SOHO State of the Art Updates and Next Questions | Individualizing Treatment Selection in Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia, 26(10), 640-648. https://doi.org/10.1016/j.clml.2026.07.010

Vancouver

Hunter AM, Bose P. SOHO State of the Art Updates and Next Questions | Individualizing Treatment Selection in Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):640-648. doi:10.1016/j.clml.2026.07.010

BibTeX
@article{Hunter2026,
  author = {Hunter, Anthony M and Bose, Prithviraj},
  title = {SOHO State of the Art Updates and Next Questions | Individualizing Treatment Selection in Myelofibrosis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {10},
  pages = {640--648},
  doi = {10.1016/j.clml.2026.07.010}
}
Kostenlos starten →